Ufiprazole can be synthesized by the condensation reaction of 2-mercapto-5-methoxybenzimidazole and 2-chloromethyl-4-methoxy-3,5-lutidine.
Omeprazole sulfide is an intermediate used in the production of the gastric proton pump inhibitors, omeprazole and esomeprazole . As a degradation product, it is reported to be a direct-acting inhibitor of cytochrome P450 2C19 in pooled human liver microsomes (IC50 = 9.7 μM).
Omeprazole Sulfide (Esomeprazol EP Impurity C(Omeprazole EP Impurity C)) is a metabolite of Omeprazole.
ChEBI: Omeprazole sulfide is a member of benzimidazoles.
Ufiprazole (Omeprazole sulfide) is an intermediate in the production of gastric proton pump inhibitors omeprazole and esomeprazole.
[1] Patent: CN108409714, 2018, A. Location in patent: Paragraph 0049-0054; 0063-0067; 0076-0080; 0089-0093
[2] Patent: CN106632256, 2017, A. Location in patent: Paragraph 0008
[3] Patent: CN107400117, 2017, A. Location in patent: Paragraph 0058-0060
[4] Patent: CN107400118, 2017, A. Location in patent: Paragraph 0046; 0047; 0048
[5] Patent: WO2011/12957, 2011, A1. Location in patent: Page/Page column 16
